Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,918 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: MRS Clear all

Conditions: Renal Cell Carcinoma
Interventions: MRI with ASL, ASL-MRI; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Thyroid Cancer
Interventions: Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT); Drug · Procedure
Lead sponsor: Thomas Hope; Other
Eligibility: 13 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioblastoma Multiforme, Glioblastoma - Category
Interventions: Bevacizumab, Magnetic Resonance Spectroscopy (MRS), Border Zone Stereotactic Radiosurgery (BZ-SRS); Drug · Procedure
Lead sponsor: Ajay Niranjan; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
Interventions: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Chemotherapy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 194
States / cities: Kingman, Arizona • Phoenix, Arizona • Beverly Hills, California + 151 more

Conditions: Coronary Artery Disease, Myocardial Ischemia, Heart Disease
Interventions: SPECT imaging, PET imaging; Other
Lead sponsor: Hartford Hospital; Other
Eligibility: 50 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 5
States / cities: Huntsville, Alabama • Hartford, Connecticut • Kansas City, Missouri + 2 more

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Hyperpolarized Bicarbonate (13C), Magnetic Resonance imaging; Drug · Procedure
Lead sponsor: Robert Flavell, MD, PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus, Stage II Esophageal Cancer, Stage II Gastric Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer
Interventions: erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose F 18; Drug · Radiation · Procedure + 2 more
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Cancer
Interventions: DCE-MRI, DW-MRI and MRS; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Nab-paclitaxel, Oxaliplatin, Radiation Therapy, Surgical Procedure; Procedure · Other · Drug + 1 more
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma (Skin)
Interventions: iodinated contrast dye, computed tomography, positron emission tomography, fludeoxyglucose F 18; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Cervical Neoplasms
Interventions: MR Spectroscopy, Fat-Saturation and Diffusion-Weighted Imaging, Dynamic Contrast Enhancement MRI (MR-DCE), Diffusion Tensor Imaging (DTI); Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure; Procedure · Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia

Conditions: Healthy
Interventions: onabotulinumtoxinA; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 30 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Irvine, California

Conditions: Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
Interventions: PET scan with 124I-cRGDY-PEG-dots; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions: Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography; Radiation · Other · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 1,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tricuspid Valve Regurgitation, Non-rheumatic, Mitral Valve Regurgitation
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions: ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Drug · Procedure · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 22 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions: Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Months to 25 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
Interventions: Risk Map Decision Support System (DSS)., Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging (MRI) Guided Biopsy; Other · Radiation · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • Portland, Oregon

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Biological + 2 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 476
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more

Conditions: Glioblastoma Multiforme of Brain
Interventions: Standard Radiation Therapy, Standard Temozolomide, Belinostat; Radiation · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Breast Cancer, Stage IV Breast Cancer
Interventions: positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis; Procedure · Radiation · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Brain Neoplasms
Interventions: Intracranial Catheter Placement, Lumbar Puncture, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Minutes and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 278
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more

Search by objective public record fields.

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

Rubidium-82 Position Emission Computed Tomography (PET) Versus Gated, Rest / Stress Technetium 99-m SPECT

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma

MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Functional Effects of Botox on the Brain Using MRS and fMRI

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Atrioventricular Valve Regurgitation Vena Contracta; Echo Versus MRI

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)